TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Aura Biosciences Inc ( (AURA) ) has issued an update.
On November 13, 2025, Aura Biosciences reported its third-quarter financial results and business highlights, emphasizing its focus on clinical execution in trials for early choroidal melanoma and non-muscle invasive bladder cancer (NMIBC). The company announced that enrollment for the Phase 3 CoMpass trial in early choroidal melanoma is expected to complete in 2026, with topline data anticipated in late 2027. The Phase 1b/2 trial for NMIBC is on track, with data expected in mid-2026. Aura Biosciences also highlighted the potential of bel-sar to transform treatment paradigms in ocular and urologic oncology, aiming to address high unmet medical needs with its innovative therapies.
The most recent analyst rating on (AURA) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Aura Biosciences Inc stock, see the AURA Stock Forecast page.
Spark’s Take on AURA Stock
According to Spark, TipRanks’ AI Analyst, AURA is a Neutral.
Aura Biosciences’ overall stock score reflects its early-stage biotech profile, characterized by no revenue, increasing losses, and negative cash flows. While the company maintains a solid balance sheet, its stock faces bearish technical indicators and speculative valuation. The recent board appointment is a positive development, but the company’s financial health and market trends remain the primary concerns.
To see Spark’s full report on AURA stock, click here.
More about Aura Biosciences Inc
Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Their lead candidate, bel-sar (AU-011), is in late-stage development for early choroidal melanoma and early-stage development in other ocular oncology indications and bladder cancer. Aura Biosciences is headquartered in Boston, MA.
Average Trading Volume: 245,406
Technical Sentiment Signal: Sell
Current Market Cap: $346M
For an in-depth examination of AURA stock, go to TipRanks’ Overview page.